Categories

• Announcements

  Announcements regarding our community

  2
  Topics
  12
  Posts

  

  @Jennifer-Carroll I've solicited feedback from ANTIBODY's Creative Director, Melisa Barrilli, who had the following thoughts to offer on the bilingual logo: Although we rarely use bilingual logos, they do come in handy. Glad a version was created! The bilingual logo seems to have optimized the space and flows well. Legibility seems excellent for the PAAB/CCPP words. It will be interesting to see how all versions look when applied at their minimum recommended size—there's considerable size variation with the smaller type, so "Reviewed by" may become illegible if used too small. Hope this is useful!
• Tours

  A place for patient and healthcare professional feedback.

  5
  Topics
  5
  Posts

  A

  Enter your comments here.
• About

  Want to know more about the organization, strategic plan, services, and fee schedule? Ask here.

  1
  Topics
  2
  Posts

  

  @NatBourre You can see the link to the community guidelines in the top right corner of the forum or it will be a link available on all pages of the updated PAAB website.
• PAAB Forum Tutorials

  Have questions about how to use the forum, set up your account, functionality etc.? Ask them here and we'll help you out.

  1
  Topics
  1
  Posts

  A

  Lets start with a quick registration video.
• Newsletters/Blogs

  Blog posts from individual members

  5
  Topics
  29
  Posts

  R

  @Jennifer-Carroll Ah. Thanks for clarifying. I misunderstood that question 466 was in relation to attaching an approved template, and not just for a regular email. Thanks for the quick response!
• PAAB Code

  Do you have questions about particular sections of the PAAB code? Do you have insights on how sections of the code be improved? Do you want to share insights about how related standards are addressed in other jurisdictions? Post here.

  16
  Topics
  18
  Posts

  

  Hey @Helen Section 6.6 was revised and repositioned to 1.5. Alternatively, this may have been a typo in the response letter. Please follow up with your reviewer if section 1.5 does not address the issue. With regards to archived versions of the Code, per PAAB Q&A 717, the PAAB website only contains the most recent version of the code so as to clearly promote current best practices.
• Events & Training

  Have more questions about training? Let us know.

  0
  Topics
  0
  Posts
  No new posts.
• Resources

  Guidance on Code Application

  Guidance on Submission Procedures

  Guidance on DTCA / DTCI Regulations

  Newsletters

  PAAB Icons

  Activities

  External Resources
  69
  Topics
  74
  Posts

  A

  Enter your comments for this document here
• PAAB Q&A

  Claims & Support/References for Claims

  Non-product branded APS, pre-NOC teasers

  NHP, OTC

  CME, educational material, Reprints, reports, textbooks, independently created content

  DTCA/I, consumer secondary audience

  Electronic Media

  FYI post-approval change/preclearance exemption/what requires review/PAAB scope

  Miscellaneous

  Disclosure requirements: PI & Safety Information, Federal schedule, study parameters, reference lists

  Giveaways, Incentives & GIfts, contests, coupons (maybe activities)

  International Conferences

  Linkage Issues

  Patient Info

  Press Releases, Financial Reports, Unsolicited Requests

  Sampling

  Submission Requirements/process & Timelines/eFiles

  Terms of Market Authorization

  Visuals/Layout
  745
  Topics
  780
  Posts

  G

  Hi PAAB, I saw your guidance on the use of RWE here (https://www.paabtraining.com/rwe.html) and I am wondering if this extends to 'high quality' studies in which the efficacy of two or more products is compared? For example - an observational study including data from patients using several products? Thank you for your time!